Toronto · Pre-Seed–Late Stage · 18 people tracked
Also known as LUMIRA CAPITAL INVESTMENT MANAGEMENT INC.
Investment thesis
Lumira Ventures backs mission-driven entrepreneurs building transformative life sciences companies. The firm focuses on developing and commercializing impactful products aimed at improving outcomes for patients, positioning itself as a leading North American life sciences investor.
Source: firm website, verified Aug 25, 2026.
Team · 18 people
from the firm's website & public directories
What they invest in
from 48 of 57 portfolio companiesBiotech ×36Healthtech ×29Medical Devices ×25Digital Health ×12Deep Tech ×9Hardware ×5AI & Machine Learning ×3Advanced Manufacturing ×1
HQs:United States×25Canada×5United Kingdom×1
Who they back
founder profiles across 19 portfolio companiesFounding team size:solo founder×82 founders×53 founders×34+ founders×3
Investments · 57 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22024 · 32023 · 12022 · 12020 · 22019 · 22017 · 12016 · 12015 · 22014 · 119 dated
Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases.
BiotechHealthtechMarkham, US
Pardeep Nijhawan(Executive Officer, Director)Stephen Lemieux(Executive Officer)Michael Brooks(Executive Officer)Mary Catherine Brisson(Executive Officer)Mark A. McPartland(Executive Officer)Kathi Niffenegger(Executive Officer)
Co-investorsVenture Ontario
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)GORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)SURJIT DIXIT(Executive Officer)DAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Nextech InvestWUTIF Capital
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)Warren Douglas Sheffield(Executive Officer, Director, Promoter)
Board seatGerry Brunk· per SEC Form D
Co-investorsJAZZ Venture PartnersAngelini VenturesF-Prime CapitalIaso Ventures
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)Guillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)Jeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)
Board seatGerry Brunk· per SEC Form D
Co-investorsS3 VenturesSV Health InvestorsDeerfield Management CompanyJohnson & Johnson Innovation – JJDC
Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.
BiotechDeep TechMedical DevicesSan Diego, US
Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)Frank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))Raymond W. Urbanski(Acting Chief Medical Officer)David Stirling, PhD(Executive Officer, Director)
Co-investorsRevelation PartnersSR One Capital Management
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalRoche Venture FundAngelini VenturesJDRF T1D Fund
Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.
BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US
Rick Geoffrion(Founder, President and CEO & Board Member)
Co-investorsRemiges Ventures, Inc.DeepWork Capital
Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.
HardwareHealthtechMedical DevicesMontreal
FRANCOIS TRUDEAU(Executive Officer, Director)JADE DOUCET-MARTINEAU(Executive Officer, Director)Jade Doucet-Martineau(Co-founder & CEO, Board Director)François Trudeau(Co-founder & CTO, Board Director)Philippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)Maxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)
Co-investorsBroadview VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+1 more
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).
BiotechDigital HealthMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)Debra Odink(President & Chief Development Officer)Amy Sehnert(Chief Medical Officer)Matt Killeen(Chief Business Officer)
BoardSaumya Das(Chief Scientific Advisor)
Co-investorsadMare BioInnovationsAmzak HealthCTI Life Sciences Fund L.P.Fonds de solidarité FTQ
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)James Cohen(Director)
Co-investorsFountain Healthcare PartnersJeito CapitalLongwood FundSofinnova Ventures
BiotechAtlanta, US
Eric Springman(Executive Officer)Sanjeev Ahuja, M.D.(Executive Officer)Greg Duncan(Executive Officer, Director)William P. Reddick(Executive Officer)
BoardMaxim Gorbachev(Director)Nicole Vitullo(Director)
Board seatGerry Brunk· per SEC Form D · $40M raise · filed Jun 2015
Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.
BiotechTewksbury, US
George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)
BoardPaul LaViolette(Director)inKevin Gillis(Director)inGerald Brunk(Director)inIrit Yaniv(Director)
Board seatGerry Brunk· per SEC Form D · $34M raise · filed Sep 2015
Co-investorsAccelmed PartnersSV Health InvestorsThird Rock Ventures
Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
HealthtechWashington, US
Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)
BoardTakahide Koda(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsRemiges Ventures, Inc.DeepWork Capital
Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.
Digital HealthHealthtechMedical DevicesWoodridge, US
Harry Rowland(Executive Officer, Director)Anthony I Nunez(Executive Officer, Director)Anthony Nunez(Founder)inAnthony A. Nunez(Executive Officer, Director)
BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsBioventures InvestorsJumpstart VenturesOSF VenturesSeroba Life SciencesSV Health Investors
Company whose formation and launch the LifeSci team supported.
BiotechHealthtechSummit, US
Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)Orrin Devinsky(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsLifeSci Venture Partners
Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.
HardwareHealthtechMedical Devices
Randy AuCoin(President & CEO)
Board seatPeter van der Velden· per SEC Form D
Co-investorsiGan PartnersPMVVenture OntarioVesalius Biocapital Partners
HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.
BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB
Wen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)James Adox(Director)Thomas Davison(Executive Officer, Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsAlpha Wave GlobalAmzak HealthEarly Stage Partners, LPHealthQuest CapitalMichigan Capital NetworkBezos Expeditions+2 more
BiotechVerdun
Stephen Nelson(Director)Adele Gulfo(Director)Ken d'Entremont(Executive Officer, Director)Roland Boivin(Executive Officer)Terri Shoemaker(Executive Officer)Michael Mueller(Director)
Board seatPeter van der Velden· per SEC Form D · $400K raise · filed Mar 2020
BiotechBoston, US
Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)
Board seatGerry Brunk· per SEC Form D · $35M raise · filed Oct 2022
Co-investorsAdvent Life SciencesOrbiMed
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalNextech Invest+8 more
Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD.
BiotechHealthtech
C Vivek Lal(Founder & CSO)Amit Gaggar(Chief Medical Officer)inGaurav Mehta(CEO)in
AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells.
BiotechDigital HealthMedical DevicesToronto, CA
Mike Cooke(Co-Founder & CEO)Molly Shoichet(Co-Founder & Chief Science Officer)
Co-investorsStand Up VenturesToronto Innovation Acceleration Partners
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)John Sayward(Executive Officer)
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersMPM BioImpactOUP (Osage University Partners)Sofinnova Ventures+2 more
Co-investorsSunstone Capital
BiotechVictoria
Kurt von Emster(Director)Benjamin Rovinski(Director)Chris Kim(Director)Donald Wyatt(Director)Stephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)
Co-investorsNew Enterprise Associates (NEA)venBio Partners
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical DevicesSeattle, US
Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)
Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesRC CapitalRex Health VenturesSV Health Investors+1 more
Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections.
BiotechDeep TechToronto, CA
Leah Cowen(Co-founder & CSO)Luke Whitesell(Co-founder & Consultant)Dominic Jaikaran(President & CEO)
Co-investorsToronto Innovation Acceleration Partners
Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.
BiotechHealthtechMedical DevicesKirkland, US
Kurt Wheeler(Director)Frederick A. Stewart(Executive Officer, Director)Richard O. Martin(Director)Nathan Every(Director)Douglas C. Fisher(Director)Rick Wypych(Executive Officer)
Co-investorsAPERTURE Venture PartnersRedbus VenturesAlly Bridge GroupClaret Capital PartnersM.H. Carnegie & Co.
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)
Co-investorsOrbiMedAlexandriaDIMENSIONBDC Thrive Venture Fund for Women
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin S Eisenfrats(Executive Officer, Director, Promoter)Kevin Eisenfrats(Co-Founder and CEO)John Herr(Co-Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)
Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture Capital+14 more
Co-investorsAccelmed Partners
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalMenlo Ventures+5 more
Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsAngelini VenturesNoeticToronto Innovation Acceleration Partners
BiotechGermantown, US
John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)
Co-investorsPlains Ventures
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Stacey Pugh(Leadership (CEO))Chris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in
Co-investorsArboretum VenturesIntuitive VenturesLongitude Capital
enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.
BiotechMedical Devices
Co-investorsCTI Life Sciences Fund L.P.
Co-investorsToronto Innovation Acceleration Partners
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapSeroba Life SciencesVenture OntarioYsios CapitalAdams Street Partners+2 more
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Mark A. Velleca(Executive Officer, Director)inTimothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)Ron Laufer(Director)Michael Gutch(Director)
Co-investorsMountain Group CapitalRA CapitalSolasta VenturesHatteras Venture Partners
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway.
BiotechHealthtech
Rahul Aras(Chief Executive Officer)Ovid Trifan(Chief Medical Officer)inSteve Horrigan(Chief Scientific Officer)in
Co-investorsGreen Park & Golf VenturesPortal Innovations
KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.
AI & Machine LearningBiotechDeep Tech
Co-investorsRemiges Ventures, Inc.
Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.
HardwareHealthtechMedical Devices
Co-investorsFoothill VenturesShangBay Capital LLCUS Venture PartnersAmzak Health
OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.
Digital HealthMedical Devices
Stryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers.
Advanced ManufacturingHealthtechMedical Devices
Kevin Loboin
Co-investorsGefinor CapitalNew Enterprise Associates (NEA)Rex Health VenturesWindham Capital Partners
SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.
HardwareHealthtechMedical Devices
Jeremy Brown(Co-Founder & CTO)inMatt Mallay(Co-Founder & Sr. Dir. R&D)inAndre Bezanson(Co-Founder & Dir. R&D)inEli Vlaisavljevich(Co-Founder)inRick Balys(Co-Founder)inNeil Barman(Chief Executive Officer)in
Co-investorsAmzak HealthInvest Nova Scotia
Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats.
BiotechDeep TechHealthtech
HealthtechSunnyvale, US
David Milne(Director)Thomas Afzal(Executive Officer, Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
BoardPeter van der Velden(Director)
Co-investorsHLM Venture PartnersSV Health InvestorsSV Life Sciences
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Co-investorsNew Enterprise Associates (NEA)Partners ResoluteThynk Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioEdesa BiotechNASDAQ: EDSAZymeworksNASDAQ: ZYMEGuavatechnologiesacq. by Cytek Biosciences
Portfolio news
latest coverage across their companiesenGene · marketbeat.com · Aug 15, 2026
Contraline · fiercebiotech.com · Aug 12, 2026
Edesa Biotech · stocktitan.net · Jul 14, 2026
Congruencetx · geekwire.com · Jul 13, 2026
Zymeworks · finance.yahoo.com · Jul 1, 2026
Medexus · investing.com · Jun 26, 2026
Nervonik · citybiz.co · Apr 28, 2026
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2024
Disclosed stake · filed Jan 2023
Disclosed stake · filed Jan 2020
Disclosed stake · filed Sep 2019
Disclosed stake · filed Aug 2019
Disclosed stake · filed Jun 2019
Disclosed stake · filed Feb 2018
Disclosed stake · filed Apr 2017
8 insider ownership filings (Forms 3/4/5)
at enGene Holdings Inc. (ENGN), Edesa Biotech, Inc. (EDSA)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Lumira Ventures made?
- Lumira Ventures has 51 tracked investments, 1 of which have exited via acquisition or IPO, including 8 dated in the last 24 months.
- What stage does Lumira Ventures invest at?
- Lumira Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Lumira Ventures's typical check size?
- Lumira Ventures typically writes checks of $1M – $10M.
- What sectors does Lumira Ventures focus on?
- Lumira Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Lumira Ventures located?
- Lumira Ventures is headquartered in Toronto, CA.
- Who does Lumira Ventures co-invest with?
- Lumira Ventures most often shares deals with New Enterprise Associates (NEA), SV Health Investors, Toronto Innovation Acceleration Partners, among 108 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.